Immatics shares early bispecific data as it seeks to make its name beyond cell therapy

Immatics' early clinical data on TCR bispecifics IMA401 and IMA402, showing promising response rates in heavily pretreated solid tumor patients, positions the company as a leader in PRAME-targeting therapies. Bristol Myers Squibb's exit and Immatics' plans for further development and combination trials indicate significant potential for advancing bispecific platforms in oncology.